Sandy Macrae - 24 May 2024 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
SGMO
Transactions as of
24 May 2024
Net transactions value
-$7,652
Form type
4
Filing time
29 May 2024, 16:54:22 UTC
Previous filing
27 Feb 2024
Next filing
27 Aug 2024

Quoteable Key Fact

"Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 29 May 2024."

Quick Takeaways

  • This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Filing timestamp: 29 May 2024, 16:54.

What Changed

  • Previous filing in this sequence was filed on 27 Feb 2024.
  • Current net transaction value: -$7,652.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability $3,157 -5,261 -0.21% $0.6000 2,546,943 24 May 2024 Direct F1, F2, F3
transaction SGMO Common Stock Tax liability $4,495 -7,492 -0.29% $0.6000 2,539,451 25 May 2024 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2 Includes: (a) 9,485 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 103,229 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 84,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
F3 The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4 Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F5 Includes: (a) 13,508 shares resulting from the from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 63,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 103,229 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .